Alphabet Replaces Verizon in Dow Jones Industrial Average 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
CAMBRIDGE, Mass., Feb. 04, 2016 -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases, announced today that the company will participate in the Leerink Partners 5th Annual Global Healthcare Conference in New York City. Chief Executive Officer Mary Szela and Chief Financial and Administrative Officer Gregory Perry are scheduled to present in a fireside chat on Thursday, February 11, 2016 at 3:30 p.m. ET.
The presentation will be webcast live and may be accessed for up to 30 days following the conference by visiting the “Investors” section of Aegerion’s website, www.aegerion.com.
About Aegerion Pharmaceuticals
Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. For more information about the company, please visit www.aegerion.com.
CONTACT: Aegerion Pharmaceuticals, Inc. Amanda Murphy Associate Director, Investor Relations 857-242-5024
